Capturing the Value of R&D
Worried about a likely gap in earnings, many drug companies want to increase the number of products in their pipelines. But such productivity driven strategies hav estrained development and commercialization resources while advancing mediocre compounds, compromising marketplace results. Yield-led companies have done far better, focusing on fewer, better products and devoting adequate resources to their development and launch.
You may also be interested in...
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Medicare now covers transcatheter edge-to-edge repair for both functional and degenerative mitral regurgitation under specific conditions.